The activation peptide of thrombin-activatable fibrinolysis inhibitor: A role in activity and stability of the enzyme?

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 3, 2009, Pages 445-452

  Marx, Pauline F ^a   Plug, T ^a   Havik, S R ^a   Morgelin M ^b   Meijers, J C M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Carboxypeptidase R; Carboxypeptidase U; Fibrinolysis; Protein aggregation; TAFI

Indexed keywords

CARBOXYPEPTIDASE; ENZYME PRECURSOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; CELL STRAIN HEK293; CENTRIFUGATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME METABOLISM; ENZYME STABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION;

CARBOXYPEPTIDASE U; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME STABILITY; HALF-LIFE; HUMANS; HYDROLYSIS; PEPTIDE HYDROLASES; PEPTIDES; SOLUBILITY;

EID: 59849100558     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03249.x     Document Type: Article

References (18)

1. Marx PF. Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem 2004; 11: 2311-24.
2. Boffa M, Wang W, Bajzar L, Nesheim M. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/ thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
3. Schneider M, Boffa M, Stewart RJ, Rahman NL, Koschinsky ML, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
4. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
5. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896-904.
6. Mao SS, Colussi D, Bailey CM, Bosserman M, Burlein C, Gardell SJ, Carroll SS. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. Anal Biochem 2003; 319: 159-70.
7. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI; a novel mechanism for enzyme auto-regulation. Blood 2008; 112: 2803-9.
8. Anand K, Pallares I, Valnickova Z, Christensen T, Vendrell J, Wendt KU, Schreuder HA, Enghild JJ, Aviles FX. The crystal structure of TAFI provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 2008; 283: 29416-33.
9. Buelens K, Hillmayer K, Compernolle G, Declerck PJ, Gils A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res 2008; 102: 295-301.
10. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JCM, Bouma BN. Inactivation of activated thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-15.
11. Marx PF, Wagenaar GTM, Reijerkerk A, Tiekstra MJ, Van Rossum AG, Gebbink MF, Meijers JC. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 2000; 83: 297-303.
12. Willemse J, Leurs J, Verkerk R, Hendriks D. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal Biochem 2005; 340: 106-12.
13. France RM, Sellers DS, Grossman SH. Purification, characterization, and hydrodynamic properties of arginine kinase from gulf shrimp (Penaeus aztecus). Arch Biochem Biophys 1997; 345: 73-8.
14. Yu CJ, Lin YF, Chiang BL, Chow LP. Proteomics and immunological analysis of a novel shrimp allergen, Pen m 2. J Immunol 2003; 170: 445-53.
15. Pahlman LI, Marx PF, Morgelin M, Lukomski S, Meijers JC, Herwald H. Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem 2007; 282: 24873-81.
16. Guimaraes AH, Barrett-Bergshoeff MM, Gils A, Declerck PJ, Rijken DC. Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. J Thromb Haemost 2004; 2: 780-4.
17. Strömqvist M, Hansson L, Andersson J, Johansson T, Edlund M, Enoksson M, Goossens F, ScharpéS, Hendriks D. Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells. Clin Chim Acta 2004; 347: 49-59.
18. Strömqvist M, Schatteman K, Leurs J, Verkerk R, Andersson J, Johansson T, Scharpé S, Hendriks D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 12-17.